ResearcherParacelsus Medical UniversityActive in the last 2 years
Lukas Weiß
Matched on ORCID iD 0000-0002-2174-5613; OpenAlex author ID A5006219111. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 6
- Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? Co-author DOI 10.21203/rs.3.rs-4461811/v1↗
- Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-c… Last author DOI 10.1002/cam4.6334↗
- Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.09.004↗
- Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Co-author DOI 10.1177/15330338211042139↗
- C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm8111791↗
- Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. Co-author DOI 10.1371/journal.pone.0206688↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Konstantin Schlick · 6 shared papers, 2018–2024 · strength 0.88
- Paper Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanc… DOI 10.1002/cam4.6334↗
- Paper Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? DOI 10.21203/rs.3.rs-4461811/v1↗
- Paper Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospecti… DOI 10.1177/15330338211042139↗
- Richard Greil · 6 shared papers, 2018–2024 · strength 0.88
- Paper Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanc… DOI 10.1002/cam4.6334↗
- Paper Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? DOI 10.21203/rs.3.rs-4461811/v1↗
- Paper Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospecti… DOI 10.1177/15330338211042139↗
- Alexander Egle · 3 shared papers, 2018–2021 · strength 0.29
- Paper Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic c… DOI 10.1016/j.pan.2021.09.004↗
- Paper C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in P… DOI 10.3390/jcm8111791↗
- Paper Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically ava… DOI 10.1371/journal.pone.0206688↗
- Daniel Neureiter · 2 shared papers, 2021 · strength 0.27
- Paper Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospecti… DOI 10.1177/15330338211042139↗
- Paper Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic c… DOI 10.1016/j.pan.2021.09.004↗
- Armin Gerger · 1 shared paper, 2024 · strength 0.21
- Jakob Michael Riedl · 1 shared paper, 2024 · strength 0.21
- Martin Pichler · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.